Judith Straimer

List of Publications by Year
in descending order

18 papers	2,518 citations	471509 17 h-index	839539 18 g-index
20 all docs	20 docs citations	20 times ranked	2697 citing authors

#	Article	IF	Citations
1	K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates. Science, 2015, 347, 428-431.	12.6	563
2	A Worldwide Map of<i>Plasmodium falciparum</i>K13-Propeller Polymorphisms. New England Journal of Medicine, 2016, 374, 2453-2464.	27.0	449
3	Artemisinin Action and Resistance in Plasmodium falciparum. Trends in Parasitology, 2016, 32, 682-696.	3.3	271
4	Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance. PLoS Biology, 2015, 13, e1002132.	5.6	254
5	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nature Communications, 2016, 7, 11553.	12.8	208
6	Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nature Methods, 2012, 9, 993-998.	19.0	149
7	<i>Plasmodium falciparum</i> K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness <i>In Vitro</i>. MBio, 2017, 8, .	4.1	103
8	Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. ELife, 2021, 10, .	6.0	85
9	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Scientific Reports, 2013, 3, 3318.	3.3	75
10	Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparumÂK13. PLoS Pathogens, 2020, 16, e1008482.	4.7	60
11	High Prevalence of <i>Plasmodium falciparum</i> K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine. Journal of Infectious Diseases, 2022, 225, 1411-1414.	4.0	54
12	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	12.8	51
13	Balancing drug resistance and growth rates via compensatory mutations in the <scp><i>P</i></scp><i>lasmodium falciparum</i> chloroquine resistance transporter. Molecular Microbiology, 2015, 97, 381-395.	2.5	47
14	Artemisinin resistance phenotypes and K13 inheritance in a <i>Plasmodium falciparum</i> cross and <i>Aotus</i> model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12513-12518.	7.1	46
15	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Doseâ€“Efficacy Modeling. PLoS Medicine, 2016, 13, e1002138.	8.4	35
16	Editing the<i>Plasmodium vivax</i>Genome, Using Zinc-Finger Nucleases. Journal of Infectious Diseases, 2015, 211, 125-129.	4.0	25
17	Generation of Transmission-Competent Human Malaria Parasites with Chromosomally-Integrated Fluorescent Reporters. Scientific Reports, 2019, 9, 13131.	3.3	22
18	Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated <i>Plasmodium falciparum</i> Malaria. Clinical Infectious Diseases, 2022, 74, 1831-1839.	5.8	21